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Background:Acutemyeloid leukemia (AML) patients with highly active AKT tend to do poorly. Cell cycle arrest and
apoptosis are tightly regulated by AKT via phosphorylation of GSK3α and β isoforms which inactivates these
kinases. In the current study we examine the prognostic role of AKT mediated GSK3 phosphorylation in AML.
Methods:We analyzed GSK3α/β phosphorylation by reverse phase protein analysis (RPPA) in a cohort of 511 acute
myeloid leukemia (AML) patients. Levels of phosphorylated GSK3 were correlated with patient characteristics
including survival and with expression of other proteins important in AML cell survival.
Results:High levels of p-GSK3α/β correlated with adverse overall survival and a lower incidence of complete
remission duration in patients with intermediate cytogenetics, but not in those with unfavorable cytogenetics.
Intermediate cytogenetic patients with FLT3 mutation also fared better respectively when p-GSK3α/β levels
were lower. Phosphorylated GSK3α/β expression was compared and contrasted with that of 229 related cell
cycle arrest and/or apoptosis proteins. Consistent with p-GSK3α/β as an indicator of AKT activation, RPPA
revealed that p-GSK3α/β positively correlated with phosphorylation of AKT, BAD, and P70S6K, and negatively
correlated with β-catenin and FOXO3A. PKCδ also positively correlated with p-GSK3α/β expression, suggesting
crosstalk between the AKT and PKC signaling pathways in AML cells.
Conclusions: These ﬁndings suggest that AKT-mediated phosphorylation of GSK3α/βmay be beneﬁcial to AML
cell survival, and hence detrimental to the overall survival of AML patients. Intrinsically, p-GSK3α/βmay serve
as an important adverse prognostic factor for a subset of AML patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute myeloid leukemia (AML) remains a highly fatal disease, so a
better understanding of the signaling pathways that support leukemia
cell growth and survival is necessary in order to develop improved
therapies. Strategies designed to target signaling cascades have been
suggested as a way to optimize AML therapy [1–8]. The activation of
survival kinases such as AKT, PKC, and ERK has been shown to predict
poor clinical outcome for patients with AML [8]. AKT is a key regulator
of protein translation, transcription, cell proliferation, and apoptosis,
and is emerging as a potentially important target for AML therapy
[1,3,4,8].nit 448, The University of Texas
ouston, TX 77030, United States.
lo),
. This is an open access article underAKT has been shown to phosphorylate and inactivate GSK3, which is
a key regulator of differentiation, metabolism, apoptosis, autophagy, as
well as tumorigenesis [9–16]. Two functional isoforms of GSK3 known
as GSK3α and GSK3β are produced from separate genes, but share
97% amino acid homology [9–11]. GSK3α and GSK3β are unique
among kinases in that they are constitutively active unless their activity
is blocked by post-translational modiﬁcation such as phosphorylation
[11]. An appraisal of kinase consensus sequences revealed that GSK3
had more possible substrates than any other kinase [12,13], although
many GSK3 substrates require a “priming” phosphorylation event inde-
pendent of GSK3. The intricate regulation of GSK3 and its substrates
likely reﬂects the importance of modulating GSK3 signaling pathways
as these cascades are critical for cellular homeostasis.
A prime example of role of GSK3 role in tumorigenesis involves
the regulation of the WNT/β-catenin pathways [11,16]. GSK3 medi-
ates degradation of β-catenin by phosphorylating the molecule and
stabilizing the docking molecule (i.e., axin) required for its destruc-
tion [11,13,16]. Failure to properly regulate β-catenin can result inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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D1, and c-JUN [13]. Thus a more comprehensive, understanding of the
AKT–GSK3 signaling axis and it role in leukemogenesis is critically
needed.
In the current study, we examined the ability of GSK3 total protein
expression level, and protein activation state, based on serine 9 and/or
serine 21 phosphorylation status, to predict overall survival (OS) and
remission duration (RD) in AML patients using reverse phase protein
array (RPPA) methodology. As phosphorylation of these sites results
in inactivation of the GSK3 kinases, high phosphorylation levels indicate
lower activity of these kinase in the tumor cells. Results suggest that
AML patients with blast cells with inactivated GSK3, highly phosphory-
lated, have inferior OS and RD. RPPA revealed correlation of phospho-
GSK3 with a number of proteins including phosphorylated AKT,Table 1
Patient characteristics of all AML patients in the study.
Demographics for GSKp219
Raw numbers
Treated
All
cases
Lowest
2/3rd
Highest
3rd
P Test used
Number 511 341 170 NA Chi square
Gender M 291 203 88 0.1153
F 220 138 82
Age Min 15.8 16.01 15.83 t-Test
Max 87.23 87.23 86.8
Median 65.7 65 65.21 0.76
FAB M0 29 20 9 b0.00001 Chi square
M1 55 39 16
M2 169 127 42
M4 119 66 53
M5 50 19 31
M6 27 21 6
M7 10 7 3
RAEBT 33 29 4
Unknown 19 13 6
WHO Abnormal
cytogenetics
47 33 14 0.1 Chi square
Therapy related 73 49 24
Multilineage
dysplasia
110 83 27
Not in others 281 176 105
Cytogenetics Favorable 34 26 8 0.36 Chi square
Intermediate 225 170 82
Unfavorable 252 145 80
FLT3 ITD 83 49 34 0.145 Chi square
D835 25 17 8 0.92
Both 9
NPM1 4BP insert 55 179 89 0.76 Chi square
WT 283 35 20
ND 173 127 61
Zubrod PS 3 or 4 17 11 6 Chi square
AHD ≥2 mo 204 143 61 0.23 Chi square
Infection Yes 101 62 39 0.35 Chi square
WBC Median 8.8 6.9 19.25 0.02 F test
Absolute
blast count
Median 1.8 1.13 3.54 0.28 F test
Platelet Median 56.0 55 57 0.08 F test
Hemoglobin Median 9.6 9.6 9.45 0.15 F test
% marrow
blasts
Median 46.0 44 57 0.0002 F test
% blood blasts Median 19.0 18 20.5 0.3 F test
Response CR 231 153 78 0.17 Chi square
Resistant 136 101 35
Fail 42 21 21
Relapse Yes 151 93 58 0.09 Chi square
Alive Yes 103 76 27 0.14 Chi square
Overall
survival
Median, weeks 40.85 44.14 35.14
Remission
duration
Median, weeks 51.6 50 34.5phosphorylated PKCδ, FOXO3A, and β-catenin. These results suggest
that the AKT/GSK3 axis is critical in AML, which may be of beneﬁt to
the development of therapeutic strategies in AML patients classiﬁed
with intermediate cytogenetics.
2. Material and methods
2.1. Patient samples
Peripheral blood and bone marrow specimens were collected
from 511 patients with newly diagnosed AML evaluated at The Uni-
versity of Texas M.D. Anderson Cancer Center (MDACC) between
September 1999 and March 2007. Samples were acquired during
routine diagnostic assessments in accordance with the regulationsTreated
All
cases
Lowest
2/3rd
Highest
3rd
P Test used
Number 511 341 170 NA Chi square
Gender M 56.9% 59.5% 51.8% 0.1153
F 43.1% 40.5% 48.2%
Age Min 15.8 16.01 15.83 F test
Max 87.23 87.23 86.8
Median 65.7 65 65.21 0.76
FAB MO 5.7% 5.9% 5.3% b0.00001 Chi square
M1 10.8% 11.4% 9.4%
M2 33.1% 37.2% 24.7%
M4 23.3% 19.4% 31.2%
M5 9.8% 5.6% 18.2%
M6 5.3% 6.2% 3.5%
M7 2.0% 2.1% 1.8%
RAEBT 6.5% 8.5% 2.4%
Unknown 3.7% 3.8% 3.5%
WHO Abnormal
cytogenetics
9.2% 9.7% 8.2% 0.1 Chi square
Therapy related 14.3% 14.4% 14.1%
Multilineage
dysplasia
21.5% 24.3% 15.9%
Not in others 55.0% 51.6% 61.8%
Cytogenetics Favorable 6.7% 7.6% 4.7% 0.36 Chi square
Intermediate 44.0% 49.9% 48.2%
Unfavorable 49.3% 42.5% 47.1%
FLT3 ITD 16.7% 9.9% 6.9% 0.145 Chi square
D835 5.0% 3.4% 1.6% 0.92
Both
NPM1 4BP insert 16.3% 83.6% 81.7% 0.76 Chi square
WT 83.7% 16.4% 18.3%
ND 33.9% 37.2% 35.9%
Zubrod PS 3 or 4 3.3% 3.2% 3.5% Chi square
AHD ≥2 mo 39.9% 41.9% 35.9% 0.23 Chi square
Infection Yes 19.8% 18.2% 22.9% 0.35 Chi square
WBC Median 8.8 6.9 19.3 0.02 F test
Absolute
blast count
Median 1.8 1.1 3.5 0.28 F test
Platelet Median 56.0 55.0 57.0 0.08 F test
Hemoglobin Median 9.6 9.6 9.5 0.15 F test
% marrow
blasts
Median 46.0 44.0 57.0 0.0002 F test
% blood blasts Median 19.0 18.0 20.5 0.3 F test
Response CR 56.5% 44.9% 45.9% 0.17 Chi square
Resistant 33.3% 36.7% 26.1%
Fail 10.3% 7.6% 15.7%
Relapse Yes 65.4% 60.8% 74.4% 0.09 Chi square
Alive Yes 20.2% 22.3% 15.9% 0.14 Chi square
Overall
survival
Median, weeks 40.85 49.1
Remission
duration
Median, weeks 51.6 52
61P.P. Ruvolo et al. / BBA Clinical 4 (2015) 59–68and protocols (Lab 01-473) approved by the Investigational Review
Board of MDACC. Informed consent was obtained in accordance with
the Declaration of Helsinki. Samples were analyzed under an Institu-
tional Review Board approved laboratory protocol (Lab 05-0654).
The patient characteristics and sample preparation are described in
Table 1.
2.2. RPPA method
Proteomic proﬁling was done on samples from patients with AML
using RPPA. The method and validation of the technique are fully
described in previous publications [7,19]. Brieﬂy, patient samples were
printed in ﬁve serial dilutions onto slides along with normalization
and expression controls. Slides were probed with strictly validated
primary antibodies. Antibodies against total GSK3α/β (Santa Cruz
Biological, Catalog # 9331, primary dilution 1:200) and the serine 9
and serine 21 sites on GSK3α/B (Cell Signaling, Catalog #9331, primary
antibody dilution 1:200) were used. This same array was probed with
229 other antibodies as listed in Supplemental File 1. An IgG subtype
speciﬁc secondary antibody (1:15,000 dilution) was used to amplify
the signal and ﬁnally a stable dye is precipitated. The stained slides
were analyzed using the Microvigene software (Vigene Tech, Version
3.0) to produce quantiﬁed data.
2.3. PKCδ and FOXO3A knockdown cells
FOXO3A was knocked down in OCI-AML3 cells by lentiviral
transduction using a gene-speciﬁc shRNAmir transfer vector (Clone
V3LHS_375386 mature target sequence CGGAACGTGATGCTTCGCA,
which targets 1862–1880 on RefSeq NM_001455.3 Clone V3LHS_
641765 mature target sequence CGGCACAACCTGTCACTGC, which tar-
gets 974–992 on RefSeq NM_001455.3). PKCδ was knocked down in
THP-1 and HL60 cells by lentiviral transduction using a gene-speciﬁc
shRNA transfer vector (Clone TRCN0000010202 mature target
sequence GCAAGACAACAGTGGGACCTA, which targets 1334–1354
on RefSeq NM_006254.3) (Open Biosystems, Huntsville, AL). Lentivi-
rus was prepared by cotransfection of HEK293T cells (ATCC) with an
equimolar mix of transfer vector and packaging plasmids (psPAX2
and pMD2.G from Addgene, Cambridge, MA) using JetPrime transfec-
tion reagent as directed by the manufacturer (Polyplus, Illkirch,
France). Fresh lentiviral supernatants were passed through 0.45 μm
pore surfactant-free cellulose acetate membranes and then used at
once to infect OCI-AML3, THP-1, and HL60 cells by incubation overnight
at 37 °C under 5% CO2. OCI-AML3 cells were the kind gift from Mark
Minden (Ontario Cancer Institute; Toronto, Canada). THP-1 and HL60
cells were purchased from ATCC (Manassas, VA). Cells were subject to
selection with puromycin (Invivogen, San Diego CA) starting at
1 μg/mL. In parallel, all cells were transduced using lentivirus delivering
a non-speciﬁc control (Open Biosystems). Knockdown was veriﬁed by
Western blot analysis and by real time PCR.
2.4. Western blot analysis
Cells were treated with various doses of MK-2206 (Selleck
Chemicals) for 6 h or 5 μM GSK3 Inhibitor XVI (Calbiochem) for 6 h.
Cells were sonicated in lysis buffer (62.5 mM Tris (pH 8.0), 2% SDS,
10% glycerol, 100 μM AEBSF, 80 nM aprotinin, 5 μM bestatin, 1.5 μM E-
64, 2 μM leupeptin, 1 μM pepstatin, 500 μM sodium orthovanadate,
500 μM glycerol phosphate, 500 μM sodium pyrophosphate and 50 μM
DTT) and protein (5 × 105 cell equivalents) was subjected to electro-
phoresis using 10–14% acrylamide/0.1% SDS gels. Proteins were trans-
ferred to a nitrocellulose membrane and Western blotting analysis
was performed with antibodies against phospho-PKCδ (Cell Signaling,
Beverly, MA), PKCδ (Santa Cruz Biotechnology), phospho-GSK3α/β
(serine 9/21; Cell Signaling), GSK3α/β (Cell Signaling), MYC (Cell
Signaling), Foxo3A (Cell Signaling), and Tubulin (Sigma). Signals weredetected by using the Odyssey Infrared Imaging System andquantitated
by Odyssey software version 3.0 (both LI-COR Biosciences, Lincoln, NE,
USA). Tubulin was used as a loading control.
2.5. Statistical analyses
For RPPA, super curve algorithms were used to generate a single
value from the ﬁve serial dilutions [20]. Loading control and topograph-
ical normalization procedures accounted for protein concentration and
background staining variations [21]. Analysis using unbiased clustering
perturbation bootstrap clustering, and principle component analysis
was then done as fully described in a previous publication [7]. The
cohort was divided into sixths based on the range of expression of all
511 samples. Based on a similarity of outcomes these were collapsed
into two groups with expression in the upper third vs. the lower two
thirds for phospho-GSK3α/β. Comparison of the protein levels between
paired samples was done by performing paired t test. Association
between protein expression levels and categorical clinical variables
were assessed in R using standard t-tests, linear regression, or mixed
effects linear models. Association between continuous variable and
protein levels were assessed by using the Pearson and Spearman corre-
lation and linear regression. Bonferroni corrections were done to
account for multiple statistical parameters for calculating statistical
signiﬁcance. The Kaplan–Meier method was used to generate the
survival curves. Univariate and multivariate Cox proportional hazard
modelingwas done to investigate associationwith survivalwith protein
levels as categorized variables using the Statistica version 12 software
(StatSoft, Tulsa, OK). Although some molecular markers (NPM1, FLT3-
ITD, and RASmutations) are known for this dataset other more recently
discovered prognostic markers (e.g., DNMT3A, CEBPα, Wilms Tumor
1) are not; therefore, the multivariate analysis did not contain all
known AML prognostic markers. Overall survival was determined
based on the outcome of 415 newly diagnosed AML patients treated
at UTMDACC and RD was based on the 237 patients that achieved
remission.
3. Results
3.1. Phosphorylated GSK3β levels are elevated in a subset of AML patient
cell samples compared to normal CD34+ cells
We have used RPPA for the analysis of protein expression from
clinical samples in many hematologic malignancies [7,8,19,22–24].
Analysis of proteins of interest is possible as long as a validated anti-
body is available. We used RPPA to study total and phosphorylated
GSK3α/β (at serine 21 and serine 9, respectively) in AML blast cells
obtained from 511 newly diagnosed AML patients and CD34+ cells
obtained from 11 normal bone marrow donors. We compared phos-
phorylation status of the kinase in the AML patient set with that in
normal CD34+ cells. Total levels of GSK3β protein were signiﬁcantly
(p = 0.0059) lower in the blast cells from the AML patients com-
pared to normal CD34+ cells as shown in the histogram in Fig. 1A.
Levels of phosphorylated GSK3α/β protein were lower in the AML
cells overall (p b 0.0273; Fig. 1B) with 17.4% of cases having levels
above normal and 35.8% with levels below normal CD34+ cells.
There is a set of patients that show high levels of phosphorylated
GSK3α/β on the histogram in Fig. 1B. Differences in phosphoryla-
tion status of the kinase among various AML sub-types determined
by French–American–British (FAB) class and cytogenetic category
were very pronounced (p b 0.0001 for both categories; Supplemen-
tal Fig. S1A and B). Corresponding plots for total GSK3α/B are
shown in Supplementary Fig. S1C and D. Levels of total and phos-
phorylated GSK3α/β did not differ between diagnosis and relapse
in 47 patients with paired samples (p = 0.21 for total protein and
p = 0.31 for phosphorylated protein).
Fig. 1. GSK3 α/β total and serine 21/9 phosphorylated protein expression in AML blast cells compared to normal counterpart CD34+ cells. RPPA was performed as described in
the “Materials and methods” section. Expression of total (A) and phosphorylated (B) GSK3 α/Βwas compared in blast cells from 511 AML patients versus CD34+ bone marrow
cells from 11 normal donors.
Fig. 2. Correlation of overall survival with serine 21/9 GSK 3α/β phosphorylation levels in AML patient cytogenetic subsets. The Kaplan–Meier curve for overall survival (OS) for the total
AML patient set (A; N= 415), intermediate cytogenetic patient set (B; N= 187), and unfavorable cytogenetic patient set (C; N= 195) based on expression of phosphorylated GSK3α/β.
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outcome and shorter RD
The level of total GSK3α/β, divided at themedian,was not predictive
of remission attainment (55.5 vs. 54.8%, respectively) RD (46 vs. 46
weeks, respectively, p = 0.68), or overall survival (49 vs. 49 weeks, re-
spectively, p = .80). For survival analysis, RPPA values for phospho-
GSK3α/β were categorized into two groups (i.e., lower two-thirds and
upper one-third) based on the range of expression in all 511 cases.
However among all AML patients, thosewith higher levels of phosphor-
ylatedGSK3α/β exhibited shorter overall survival duration compared to
thosewith low levels of the phosphorylated kinase (40 vs 54weeks, re-
spectively; p = 0.015; Fig. 2A). For patients with intermediate cytoge-
netics, phosphorylated GSK3α/β predicted poor overall survival as
patients with elevated levels of phosphorylated kinase exhibited signif-
icantly shorter overall survival duration compared to patients with
lower levels of phosphorylated GSK3α/β (Fig. 2B; 56 vs 77.8 weeks, re-
spectively; p=0.018). Phosphorylation status of GSK3α/β had no effect
on overall survival duration in patients with unfavorable cytogenetics
(Fig. 2C). Likewise no difference was seen among those with favorable
cytogenetics though the patient sample size was small (N = 32; p =
0.39; data not shown).
The phosphorylation of GSK3 kinases also inﬂuenced RD. Among all
categories of AML patients that achieved remission (N= 237), patientsFig. 3. Correlation of remission durationwith serine 21/9 GSK 3α/β phosphorylation levels in AM
treated AML patient set (A; N=231), treated intermediate cytogenetic patient set (B; N=120)
on expression of phosphorylated GSK3α/β.with higher levels of phosphorylated GSK3α/β exhibited shorter RD
compared to those with low levels of phosphorylated GSK3α/β
(Fig. 3A; 43 weeks vs 67 weeks respectively; p = 0.022). Among inter-
mediate cytogenetic patients (N = 121), the inﬂuence of phosphoryla-
tion of GSK3kinase onRDwasmore pronounced as patientswith higher
levels of phosphorylated GSK3α/β displayed much shorter RD
compared to patients with low levels (Fig. 3B; 45 weeks vs 95 weeks
respectively; p = 0.0075). This correlation was observed even in the
intermediate cytogenetic patients (N = 35) with FLT3 mutation
(Fig. 3C; 24 weeks vs 50 weeks respectively; p = 0.009).
3.3. Phosphorylation of GSK3 kinases correlates with activation of AKT and
other signaling molecules in blast cells from AML patients
We have previously used RPPA to study the survival signaling path-
ways in AML blast cells including those that involve AKT [7,8,19,22–24].
RPPA was used to examine correlations of total or phosphorylated
GSK3α/β with 229 proteins in blast cells from 511 AML patients. Sixty
four proteins are signiﬁcantly correlated with total GSK3 expression in
the AML cells (p b 0.0001; R N 030; Supplemental Fig. 2). As shown in
Fig. 4, forty-four proteins showed statistically signiﬁcant (p b 0.0001,
R N 0.20) correlation with phosphorylated GSK3α/β. Twenty four pro-
teins displayed a positive correlation while twenty proteins displayed
a negative correlation with the phospho-kinase. The two proteins thatL patient cytogenetic subsets. TheKaplan–Meier curve for remission duration for the total
, and treated intermediate cytogeneticwith the FLT3mutant patient set (C; N=35) based
Fig. 4.Proteins correlatedwith phosphorylatedGSK3α/β expression inAMLpatients. Negative and positive correlation froma list of 229proteins also assayed compared to phosphorylated
GSK3α/β expression using the same reverse phase proteomics analysis on the same samples; Pearson correlation coefﬁcient R N 0.25, p b 0.001.
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are phospho-S6K1 (T389) and phospho-AKT (S473). AKT phosphorylated
at S473 reﬂects the active form of the kinase. That higher levels of
phosphorylated GSK3α/β are found when AKT is active is consistent
with AKT's role as a GSK3 kinase [11,25]. S6K1 has also been shown to
phosphorylate GSK3 kinases, though usually in the absence of TSC2 [26].
Interestingly, phosphorylated PKCδ (at both T507 and S645) was found
to be positively correlated with phospho-GSK3 levels. PKCδ has often
been viewed as a stress kinase but recent studies suggest that the enzyme
can have pro-survival properties [17,18,27,28]. A recent study by
Kinehara and colleagues suggest that PKCδ may phosphorylate GSK3
kinases in human pluripotent stem cells as part of a mechanism to
regulate stem cell renewal [28].
RPPA revealed a negative correlation between FOXO3A and phospho-
GSK3. Since FOXO3A is negatively regulated by AKT, the negative associ-
ation between phospho-GSK3 and the forkhead protein is likely an
indicator of AKT activity in the individual patients. Included among the
proteins exhibiting negative correlation with phosphorylated GSK3 is
the epidermal growth factor receptor (EGFR) phosphorylated at tyrosine
922 (Y922). EGFR is a membrane tyrosine kinase that is activated by
factors such as EGF and transforming growth factor α (TGFα). EGFR
can act as an upstream regulator of many kinase pathways includ-
ing PI3K/AKT, so a negative correlation between phosphorylated
(i.e., active) EGFR and phospho-GSK3 would be predicted. Implica-
tions of EGFR regulation of GSK3 activity, however, may be veryimportant as Du and colleagues have recently demonstrated that the
stem cell phenotype of cancer stem cellsmay be dependent on suppres-
sion of GSK3 via an EGFR/AKT axis [29]. The protein showing the stron-
gest negative correlation with phospho-GSK3 was serine 127
phosphorylated Yes Associated Protein 1 (YAP1). YAP1 is a transcrip-
tional co-activator that is part of the Hippo regulatory pathways [30,
31]. When YAP1 is phosphorylated on serine 127, it is expelled from
the nucleus and YAP1 driven gene expression decreases. While EGFR
supports YAP1 phosphorylation via PI3K, the mechanism is indepen-
dent of AKT [31]. There is no evidence that GSK3 is a YAP1 kinase. How-
ever, it is possible that GSK3 could be promoting YAP1 phosphorylation
via suppression of a protein phosphatase. GSK3 suppresses PP2A func-
tion [32] and PP2A has been shown to regulate phosphorylation of
YAP1 [30].
Considering that GSK3 serine 9/serine 21 phosphorylation levels
were signiﬁcant to survival characteristics in the intermediate cytoge-
netic AML patients, we examined protein correlations between the
phospho-kinase and the 229 proteins and the AML patients in this
subset. Most of the proteins that were represented in all AML patients
were also found in the intermediate cytogenetic group. As shown in
Fig. 5, PKCδ, phosphorylated on either threonine 507 or serine 645,
serine 473 phosphorylated AKT and serine 217/221 phosphorylated
MEK1 (MAP2K1) are still among the proteins with the strong positive
correlation with phospho-GSK3. A few proteins such as ATG7 and
EIF2S1 did not correlate with phosphorylated GSK in the intermediate
Fig. 5. Proteins correlatedwith phosphorylated GSK3α/β expression in the intermediate cytogenetic group AML patients. Negative and positive correlation from a list of 229 proteins also
assayed compared to phosphorylated GSK3α/β expression using the same reverse phase proteomics analysis on the same samples; Pearson correlation coefﬁcient R N 0.25, p b 0.001.
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3 (LGALS3) was found to correlate in the Intermediate group though
this proteinwas not in the group of total AML patients. Serine 127 phos-
phorylated YAP1, β-catenin (CTNNB1), KIT, and HIF1α (HIF1A) were
still among the proteins with strong correlation with phospho-GSK,
and two proteins not found in the total AML set, PIM1 and Asparagine
Synthase (ASNS), were found in the Intermediate subset of patients
(Fig. 5).
3.4. AKT is a positive regulator of FOXO3A and PKCδ that is independent of
GSK3
AKT is well known to regulate FOXO3A [4,5]. OCI-AML3 cells exhibit
basal levels of FOXO3A phosphorylated at threonine 32 (T32; Fig. 6A).
As shown in Fig. 6A, treatment of OCI-AML3 cells with the speciﬁc
AKT inhibitor MK-2206 suppresses T32 phosphorylation of FOXO3A
indicating that AKT is likely the FOXO3A kinase in these cells. While
GSK3 is known to phosphorylate a number of transcription factors
including MYC, MAX, and USF1 [33], the kinase is not known to target
FOXO3A. To investigate the relationship between FOXO3A and GSK3,
expression and phosphorylation status of GSK3 was compared in OCI-
AML3 cells expressing a lentiviral control vector targeting a non-human
gene (NH; target sequence for green ﬂuorescent protein; GFP) with
cells expressing lentiviral shRNA against FOXO3A. As shown in Fig. 6B,
two transductants displayed roughly 40% reductionof FOXO3A.However,
therewas no difference in either total GSK3α/β or phosphorylated kinase
in either FOXO3A shRNA transductant suggesting that FOXO3A does not
act directly onGSK3. The association between GSK3 phosphorylation sta-
tus and FOXO3A levels in the AML patient samples likely reﬂects AKT ac-
tivity in those samples (i.e. both GSK3 and FOXO3A are AKT substrates).
The inhibition of FOXO3A phosphorylation by MK-2206 (Fig. 6A) sup-
ports this hypothesis.
The RPPA data suggests that there is a positive association between
phospho-GSK3 and phospho-PKCδ (Figs. 4 and 5). Phosphorylated
GSK3 indicates that the kinase is inactive while phosphorylation of
PKCδ indicates that the kinase is active. A logical assumption would bethat PKCδ may act as a GSK3 kinase. Such a function for the PKC has
been suggested by Kinehara and colleagues [28]. PKCδ expression was
suppressed by lentiviral shRNA in two AML derived cell lines
(i.e., THP-1 and HL60). As shown in Fig. 6B, there was roughly 80% re-
duction of the kinase in THP-1 cells and approximately 60% reduction
of the PKC in HL60 cells (when compared to cells with control NH vec-
tor). Therewas no difference in either total GSK3α/β or phosphorylated
GSK3α/β in cells with PKCδ shRNA in either cell line suggesting that
PKCδ does not act directly on GSK3. The study by Kinehara and
colleagues [28] involved human pluripotent stem cells so the action of
the PKC onGSK3may be different in leukemia cells compared to normal
stem cells. A second possibility is that GSK3 acts on the PKC. OCI-AML3
cells were treated with 5 μM dose of a GSK3α/β inhibitor (Calbiochem
Inhibitor XVI) for 6 h. As shown in Fig. 6C, the inhibitor blocked GSK3
phosphorylation though the molecule induced expression of total pro-
tein. However, inhibition of GSK3 had no effect on levels of phospho-
PKCδ (Fig. 6C). MK-2206 is a speciﬁc inhibitor of AKT [35]. Treatment
of OCI-AML3 cells with 1 μMdose of MK-2206 blocked phosphorylation
of both GSK3 and PKCδ (Fig. 6C). This novel ﬁnding suggests that AKT
positively regulates PKCδ though it remains to be determined if the ki-
nase acts directly on the PKC. These results suggest that the correlation
between phospho-GSK3 levels and phospho-PKCδ levels in the AML
patient samples likely represent AKT activity in the samples (phosphor-
ylation of both GSK3 and PKCδ are positively regulated by AKT).
4. Discussion
The GSK3 kinases are involved in diverse cellular functions regulat-
ing cell growth, proliferation, survival, adhesion, and differentiation
[9–11]. These enzymes are critical for maintaining cellular homeostasis
by regulating metabolic processes (e.g., glycolysis), transcription (e.g.,
MYC and WNT pathways), translation (e.g., via mTOR), cell death pro-
cesses including apoptosis (e.g., via MCL-1) and autophagy (e.g., via
Bif-1) to name a few processes [9–14]. The GSK3 kinases are clearly
important cellular rheostats. Since GSK3 phosphorylation of survival
proteins such as MCL-1, β-catenin, and various cyclins results in the
Fig. 6. Role of GSK3α/β on AKT suppression of FOXO3A and PKCδ in AML cell lines. (A) Protein lysate (200,000 cell equivalents) from OCI-AML3 cells containing control (NS) lentiviral
plasmid or cells containing FOXO3A shRNA using 2 different lentiviral plasmids, and THP-1 cells or HL60 cells containing control (NS) lentiviral plasmid or cells containing PKCδ
shRNA lentiviral plasmid were subject to SDS/PAGE andWestern analysis performed for GSK3α/β, phosphorylated GSK3α/β, PKC d, FOXO3A, MYC, and Tubulin. Ratios were determined
by densitometric analysis of the bands depicted in theﬁgure and normalized to eachNS control. (B) Protein lysate (200,000 cell equivalents) fromOCI-AML3 cells treatedwith vehicle (-/-;
0.1 % DMS) or Calbiochem GSK3 inhibitor XVI (5 μM) or MK-2206 AKT inhibitor (1 μM) for 6 h were subject to SDS/PAGE andWestern analysis performed for GSK3α/β, phosphorylated
GSK3α/β, PKCδ, phosphorylated PKCδ, and Tubulin. Ratios were determined by densitometric analysis of the bands depicted in the ﬁgure and normalized to vehicle treated control.
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tumor suppressor [11,13]. Indeed as AKT is viewed as a pro-survival
kinase that inactivates GSK3 in many cancers including AML, this
would support strategies for AML therapy to suppress AKT and if possi-
ble, support GSK3 function. Consistent with this notion, in our RPPA
analysis of phosphorylated GSK3 AML patients from the intermediate
cytogenetic groups fare better in overall survival and in RD when they
express lower levels of phosphorylated GSK3 (see Figs. 2 and 3).
GSK3 phosphorylation status had no impact on survival or RD in
AML patients from the unfavorable cytogenetic category (see Figs. 2
and 3). The PI3K/AKT/GSK axis may not be as potent in this population
of patients or the various enzymes have different roles in these AML
cells compared to leukemia cells from the favorable/intermediate cyto-
genetic groups. Recent studies suggest there are instances where GSK3
can function as a tumor promoter [11]. Banerji and colleagues have
found that GSK3αmay act as a negative regulator of differentiation in
AML cells and thus targeting at least the α isoform of the kinase could
have therapeutic beneﬁts [34]. Scadden's group has evidence that AKTmay not be critical in leukemia stem cells and that actually FOXO3A
may play a more prominent role maintaining these cells [36]. The
possibility exists that GSKmay have a role in supporting these leukemic
stem cells [11,36]. Wang and colleagues have found that GSK3 supports
association of CREB and MEIS1, which is critical for HOX-mediated
transformation in leukemia [37]. It is likely that the role of GSK3
(or AKT for that matter) in AML is complex and likely varies from
patient to patient.
Among the 229 other proteins examined by RPPA, many of thewell-
established GSK3 substrates including SMAD1, HIF-1α, and β-catenin
were negatively correlated with phosphorylated GSK3 (Fig. 4 and
Fig. 4B) as expected. This ﬁnding is consistent with having low levels
of these target proteins when active (i.e., unphosphorylated) GSK3 is
present. Still, a number of other GSK3 targets either showed no correla-
tion (e.g. p21, MCL1; data not shown) or positive correlation (SMAD3,
Cyclin E; Fig. 4). This variability likely reﬂects the complexity of the reg-
ulatory pathways at work in AML and warrants further investigation.
Some of the proteins, such as FOXO3A that displayed a negative
67P.P. Ruvolo et al. / BBA Clinical 4 (2015) 59–68correlation with phospho-GSK3, likely do not directly interact with
GSK3, but rather are substrates of AKT like GSK3. Suppression of
FOXO3Aby shRNA in the AML cell line OCI-AML3 had no effect on phos-
phorylation status of GSK3 (Fig. 6B). However, inhibition of AKT with a
speciﬁc inhibitor (i.e., MK-2206) suppresses phosphorylation and re-
duces FOXO3A levels in the OCI-AML3 cells (Fig. 6A).
Consistent with conditions where AKT is active, RPPA revealed that
phospho-GSK3 levels were positively correlated with AKT phosphory-
lated at serine 473, with BAD phosphorylated at serine 136, and with
Ribosomal Protein S6 phosphorylated at serine 235 and 236 (Fig. 4).
These events would suggest support of leukemia survival as phosphor-
ylation of BAD at S136 inhibits its pro-apoptotic function while
phosphorylation of Ribosomal Protein S6 supports protein translation
[38]. Interestingly, there was also a strong correlation with phosphory-
lation (i.e., activation) of PKCδ at both threonine 507 and serine 645
(Fig. 4). Regulation of PKCδ by GSK3 or AKT is not clear. The reduction
of phosphorylated PKCδwith the AKT inhibitor and not the GSK3 inhib-
itor suggests that AKT may act as a PKCδ kinase. The novel possibility
suggests a new survival cascade that AKT may regulate since there is
emerging evidence that the PKCδ can act as a survival kinase [17,18].
Amodel is depicted in Fig. 7 showing some of the possible survival path-
ways thatmay be critical for AML cell survival that depend on activation
of AKT with inactive GSK3.
While it is not yet determined if inactivation of GSK3 by AKT is
required for its pro-survival function, a recent report from the Grant
lab suggests that inactivation of GSK3 is at least necessary if not sufﬁ-
cient for apoptotic pathways involving inhibition of AKT in leukemia
cells [39]. In that study, U937 cells in which GSK3 is suppressed either
by a pharmacologic inhibitor such as CHIR-98,014 or by shRNA become
resistant to killing by the PI3K/mTor inhibitor BEZ235 in combination
with the BH3 mimetic ABT-737 [39]. A mechanism whereby GSK3
activation alters expression of targets such as MCL-1, FOXO3A, CTNNB1
(β-catenin), or MYC was suggested. While in the RPPA analysis in theFig. 7.Model of AKT and GSK3α/β-mediated pathways in AML cells. Extracellular survival
signals activate AKT which suppresses GSK3α/β. When AKT is suppressed, FOXO3A and
PKCδ are inhibited independent of GSK3α/β. GSK3α/β when active will suppress MYC,
MCL-1, and β-catenin.present study no signiﬁcant correlation between phospho-GSK3 and
MCL-1 was observed, we did see expression of FOXO3A and β-catenin
negatively correlated with the phosphorylated (i.e., inactive) kinase
(Fig. 4). Studies are ongoing to determine the mechanistic role of GSK3
activation for apoptosis in AML cells.
In summary, the ﬁndings presented here suggest that GSK phos-
phorylation is likely an important event in AML patients with interme-
diate cytogenetics. Phosphorylation (i.e. inactivation) of the GSK3
kinases is associated with poor survival outcome in these AML patients.
The GSK3 targets that may be critical for leukemia cell survival remain
to be determined. Still, strategies to promote GSK3 activation by
inhibiting GSK3 kinases such as AKT or by inducing protein phospha-
tases such as PP2A could be beneﬁcial to improving therapy for at
least some AML patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbacli.2015.07.001.
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